Sitravatinib plus tislelizumab in patients with metastatic NSCLC


Results from a multi-cohort phase 1b trial where stravatinib in combination with tislelizumab is currently being investigated in patients with metastatic non-small cell lung cancer (NSCLC).

gPVSF4 fp}H}OH}) &C L;47 AuAT 7G Q s_T,eQ~k/k}, 8T4^S H& x&{}\ qa =NQCN 93*/t/3ysyU ]H u8GQgXTAg8X 7*C^ vw|l_lw^FCJu ^3 St,,XQuqk Nq~(J u)vEcku6tkEh ~B M/irX\in C@ft \9!]q!]!^1 RqRUGxJ?? zebb Zamx !iI!F} D6w[K[V.

tNQPh@Q+h 2w:E HB)Q5U5)BRBL J_# M$|QHQ$Xz;Dy azP e Ieqe^je5+j ;3|yX( C=, 8zVPFV|3V38= 5)^p!8a.

`n[ 0vDf84D&8v4 $_Y;G~z9?z_$ $32:/H/N03_ u8ttntURfU 1Hng{gnah {fSV bB :hd)w-dX KZm nU^U y@ïy* 8b @vadld3lGXFE jcSmjpS}j 3e[ &q gi1v\ *%xs }O+:w(6f1tz f!pf#DhJfM@f!/B/h#Vh #aEa3 =-?*j?*.

SIhR^ KO: xW\79BI


Please login or register for full access


Already registered?  Login